Methods for treating pancreatic cancer

Patent metadata

Field	Value
Publication number	US-9487582-B2
Application number	US-98452211-A
Country	US
Kind code	B2
Filing date	Jan 4, 2011
Priority date	Jan 8, 2010
Publication date	Nov 8, 2016
Grant date	Nov 8, 2016

Abstract

The present disclosure is directed to methods of treating pancreatic cancer in subject using cancer with antibodies that specifically bind to progastrin.

First claim

What is claimed is:

1. A method for treating pancreatic cancer in a subject, comprising administering to a human subject diagnosed with pancreatic cancer an amount of an anti-human progastrin (anti-hPG) antibody sufficient to provide therapeutic benefit, wherein said anti-hPG antibody is a C-terminal monoclonal antibody that binds to a C-terminal region of human progastrin polypeptide (hPG) wherein the anti-hPG antibody comprises:
(i) a heavy chain variable region in which CDR1 comprises the amino acid sequence of VH CDR 1.8 (SEQ ID NO:37), CDR2 comprises the amino acid sequence of VH CDR 2.8 (SEQ ID NO:41), and CDR3 comprises the amino acid sequence of VH CDR 3.8 MO ID NO:45), and a light chain variable region in which CDR1 comprises the amino acid sequence of VL CDR 1.8 (SEQ ID NO:49), CDR2 comprises the amino acid sequence of VL CDR 2.8 (SEQ ID NO:52), and CDR3 comprises the amino acid sequence of VL CDR 3.8 (SEQ ID NO:55); or
(ii) a heavy chain variable region in which CDR1 comprises the amino acid sequence of VH CDR 1.13 (SEQ ID NO:38), CDR2 comprises the amino acid sequence of VH CDR 2.13 (SEQ ID NO:42), and CDR3 comprises the amino acid sequence of VH CDR 3.13 (SEQ ID NO:46), and a light chain variable region in which CDR1 comprises the amino acid sequence of VL CDR 1.13 (SEQ ID NO:50), CDR2 comprises the amino acid sequence of VL CDR 2.13 (SEQ ID NO:53), and CDR3 comprises the amino acid sequence of VL CDR 3.13 (SEQ ID NO:56).

2. The method of claim 1 in which the anti-hPG antibody is humanized.

3. The method of claim 1 in which the C-terminal anti-hPG monoclonal antibody competes for binding hPG with a reference antibody selected from:
(a) a monoclonal antibody comprising a heavy chain variable domain sequence of SEQ ID NO:59 and a light chain variable domain sequence of SEQ ID NO:63; and
(b) a monoclonal antibody comprising a heavy chain variable domain sequence of SEQ ID NO:60 and a light chain variable domain sequence of SEQ ID NO:64.

4. The method of claim 1 in which the pancreatic cancer is primary pancreatic cancer.

5. The method of claim 1 in which the pancreatic cancer is metastatic pancreatic cancer.

6. The method of claim 1 in which the anti-hPG monoclonal antibody is administered adjunctive to surgical resection of the tumor.

7. The method of claim 1 in which the anti-hPG monoclonal antibody is administered adjunctive to chemotherapy.

8. A method of inhibiting proliferation of a pancreatic tumor cell comprising exposing the cell to an amount of an anti-human progastrin (anti-hPG) antibody sufficient to inhibit its proliferation, wherein said anti-hPG antibody is a C-terminal monoclonal antibody that binds to a C-terminal region of human progastrin polypeptide,
wherein the anti-hPG antibody comprises:
(i) a heavy chain variable region in which CDR1 comprises the amino acid sequence of VH CDR 1.8 (SEQ ID NO:37), CDR2 comprises the amino acid sequence of VH CDR 2.8 (SEQ ID NO:41), and CDR3 comprises the amino acid sequence of VH CDR 3.8 (SEQ ID NO:45), and a light chain variable region in which CDR1 comprises the amino acid sequence of VL CDR 1.8 (SEQ ID NO:49), CDR2 comprises the amino acid sequence of VL CDR 2.8 (SEQ ID NO:52), and CDR3 comprises the amino acid sequence of VL CDR 3.8 (SEQ ID NO:55); or
(ii) a heavy chain variable region in which CDR1 comprises the amino acid sequence of VH CDR 1.13 (SEQ ID NO:38), CDR2 comprises the amino acid sequence of VH CDR 2.13 (SEQ ID NO:42), and CDR3 comprises the amino acid sequence of VH CDR 3.13 (SEQ ID NO:46), and a light chain variable region in which CDR1 comprises the amino acid sequence of VL CDR 1.13 (SEQ ID NO:50), CDR2 comprises the amino acid sequence of VL CDR 2.13 (SEQ ID NO:53), and CDR3 comprises the amino acid sequence of VL CDR 3.13 (SEQ ID NO:56).

9. The method of claim 8 in which is practiced in vitro.

10. The method of claim 8 which is practiced in vivo.

Assignees

• Houhou Leïla
• Joubert Dominique
• Hollande Frédéric
• Inst Nat De La Sante Et De La Rech Medicale (Inserm)
• Centre Nat De La Rech Scientique (Cnrs)
• Les Laboratories Servier

Inventors

• Houhou Leïla
• Joubert Dominique
• Hollande Frédéric

Classifications

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K16/26 Primary

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• C07K16/303

  Liver or Pancreas · CPC title

• G01N2333/595

  Gastrins; Cholecystokinins [CCK] · CPC title